Hologic completes acquisition of Biotheranostics

Create PDF

“We are very pleased to complete the acquisition of Biotheranostics and look forward to working with our new colleagues to grow in the large, rapidly expanding oncology space,” Kevin Thornal, president of Hologic’s diagnostic solutions division, said in a press statement. “We are even more excited about the acquisition because last month the National Comprehensive Cancer Network revised its clinical practice guidelines to include Breast Cancer Index as the only gene expression assay to predict benefit from extended endocrine therapy for patients with early-stage hormone-receptor positive breast cancer.”

Both tests are laboratory-developed tests that are not required to be cleared or approved by the FDA.